文献速递其他结缔组织病

系统性硬化症自身抗体与癌症关联的全国注册研究

Association between autoantibodies in systemic sclerosis and cancer in a national registry.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

该研究基于加拿大硬皮病研究组注册库(2004–2019年)1698例SSc患者,分析自身抗体与癌症-硬皮病紧密间隔的关联。多因素logistic回归显示,抗拓扑异构酶I和抗U1-RNP阳性患者2年内癌症风险增加,而抗RNA聚合酶III未见此关联。

要点

  • 抗拓扑异构酶I阳性者2年内癌症风险增高(OR 3.43)。
  • 抗U1-RNP阳性者2年内癌症风险增高(OR 5.54)。
  • 抗RNA聚合酶III阳性与2年内癌症风险无显著关联。

核心结论

  • 在这个以女性和白人为主的SSc队列中,同步癌症罕见。
  • 抗拓扑异构酶I和抗U1-RNP阳性患者2年内癌症风险增加。
  • 抗RNA聚合酶III阳性与2年内癌症风险无显著关联。

研究设计与样本

  • 加拿大硬皮病研究组注册库2004–2019年纳入的1698例SSc患者,其中1481例(87%)有自身抗体数据。
  • 根据抗着丝点、拓扑异构酶I/Scl70、RNA聚合酶III、纤维蛋白原、Th/To(hPOP1)、PM/Scl、Ku、NOR90、Ro52/TRIM21和U1RNP抗体对患者进行特征描述。
  • 采用logistic回归分析癌症-SSc紧密间隔与自身抗体状态的关联,校正年龄、性别、种族和吸烟史。

主要发现

  • 癌症在首次非雷诺现象表现后2年、3年和5年内诊断的比例分别为1.3%、2.1%和3.5%。
  • 2年内诊断的最常见癌症为乳腺癌(33%)、妇科癌症(19%)和血液系统癌症(14%)。
  • 抗拓扑异构酶I阳性患者2年内癌症风险增高(OR 3.43,95%CI:1.04,10.05)。
  • 抗U1-RNP阳性患者2年内癌症风险增高(OR 5.54,95%CI:1.16,20.40)。
  • 抗纤维蛋白原、Th/To、PM/Scl、Ku和NOR90阳性患者中无人2年内患癌。

临床怎么用

  • 对SSc患者进行自身抗体分型有助于识别2年内癌症风险较高的亚组。
  • 抗拓扑异构酶I或抗U1-RNP阳性患者可能需要更密切的癌症筛查。
  • 基于自身抗体的筛查策略需进一步审慎考虑。

局限性

  • 同步癌症在本队列中罕见,可能限制统计效能。
  • 队列以女性和白人为主,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: A close temporal relationship between SSc onset and cancer has been reported in anti-RNA polymerase III-positive patients. We investigated the association between cancer and other SSc autoantibodies in a national SSc registry. METHODS: SSc patients enrolled in the Canadian Scleroderma Research Group registry from 2004 to 2019 were characterized according to autoantibodies to centromere, topoisomerase I/Scl70, RNA polymerase III, fibrillarin, Th/To (hPOP1), PM/Scl, Ku, NOR90, Ro52/TRIM21 and U1RNP. Logistic regression was used to examine the association between a close cancer-SSc interval and autoantibody status, adjusted for age, sex, race and smoking history. RESULTS: Of 1698 SSc patients, 1481 (87%) had available autoantibody data. Cancer was diagnosed within 2, 3 and 5 years of the first non-Raynaud manifestation in 1.3%, 2.1% and 3.5% of patients. The most frequent cancers diagnosed within 2 years were breast (33%), gynaecological (19%) and haematological (14%) cancers. The risk of cancer within 2 years was increased among anti-topoisomerase I [odds ratio (OR) 3.43, 95% CI: 1.04, 10.05] and anti-U1-RNP-positive patients (OR 5.54, 95% CI: 1.16, 20.40), but not with anti-RNA polymerase III. None of the anti-fibrillarin, Th/To, PM/Scl, Ku and NOR90-positive patients had cancer within 2 years. Patients with anti-centromere or none of the tested autoantibodies had numerically lower risks of developing cancer within two years. CONCLUSION: Synchronous cancer was rare in this large cohort of predominantly female and White SSc patients. The risk of cancer within 2 years was increased among anti-topoisomerase I and anti-U1-RNP-positive patients. Screening strategies guided by autoantibodies require further careful consideration.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Hoa S, Lazizi S, Baron M, et al. Association between autoantibodies in systemic sclerosis and cancer in a national registry. Rheumatology (Oxford). 2022. PMID: 34599801. doi:10.1093/rheumatology/keab735

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。